168 related articles for article (PubMed ID: 33439689)
1. Melflufen: A Next-Generation Nitrogen Mustard.
Holstein SA; Hillengass J; McCarthy PL
J Clin Oncol; 2021 Mar; 39(7):836-839. PubMed ID: 33439689
[No Abstract] [Full Text] [Related]
2. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
3. Melflufen for relapsed and refractory multiple myeloma.
Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of melflufen (J1)in lymphoma.
Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
[TBL] [Abstract][Full Text] [Related]
6. Melphalan Flufenamide (Melflufen): First Approval.
Dhillon S
Drugs; 2021 Jun; 81(8):963-969. PubMed ID: 33961277
[TBL] [Abstract][Full Text] [Related]
7. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC
Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276
[TBL] [Abstract][Full Text] [Related]
8. OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Schjesvold F; Robak P; Pour L; Aschan J; Sonneveld P
Future Oncol; 2020 Apr; 16(11):631-641. PubMed ID: 32141766
[TBL] [Abstract][Full Text] [Related]
9. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma.
Banerjee R; Midha S; Kelkar AH; Goodman A; Prasad V; Mohyuddin GR
Br J Haematol; 2022 Mar; 196(5):1274-1277. PubMed ID: 34750805
[No Abstract] [Full Text] [Related]
10. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Berglund Å; Ullén A; Lisyanskaya A; Orlov S; Hagberg H; Tholander B; Lewensohn R; Nygren P; Spira J; Harmenberg J; Jerling M; Alvfors C; Ringbom M; Nordström E; Söderlind K; Gullbo J
Invest New Drugs; 2015 Dec; 33(6):1232-41. PubMed ID: 26553306
[TBL] [Abstract][Full Text] [Related]
11. Melflufen for the treatment of multiple myeloma.
Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):371-382. PubMed ID: 35723075
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC
Clin Cancer Res; 2013 Jun; 19(11):3019-31. PubMed ID: 23584492
[TBL] [Abstract][Full Text] [Related]
13. Melphalan hydrochloride for the treatment of multiple myeloma.
Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C
Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983
[TBL] [Abstract][Full Text] [Related]
14. PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
Pour L; Micheva I; Usenko G; Mikala G; Masszi T; Simeonova K; Thuresson M; Huledal G; Norin S; Bakker NA; Minarik J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e267-e275.e2. PubMed ID: 38490927
[TBL] [Abstract][Full Text] [Related]
15. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
Gebraad A; Ohlsbom R; Miettinen JJ; Emeh P; Pakarinen TK; Manninen M; Eskelinen A; Kuismanen K; Slipicevic A; Lehmann F; Nupponen NN; Heckman CA; Miettinen S
Cells; 2022 May; 11(9):. PubMed ID: 35563880
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.
Huledal G; Ruiz-Garcia A; Kawakatsu S; Wang X; Sjöberg P; Gullbo J; Pekar D; Norin S; Jerling M
J Clin Pharmacol; 2024 Feb; 64(2):240-252. PubMed ID: 37752623
[TBL] [Abstract][Full Text] [Related]
17. 200 mg/m(2) melphalan--the gold standard for multiple myeloma.
Giralt S
Nat Rev Clin Oncol; 2010 Sep; 7(9):490-1. PubMed ID: 20798699
[No Abstract] [Full Text] [Related]
18. Complex hypodiploid acute myeloid leukaemia secondary to chemotherapy for hyperdiploid multiple myeloma.
Mohamed M; Dun K
Int J Hematol; 2014 Jul; 100(1):3-6. PubMed ID: 24820637
[No Abstract] [Full Text] [Related]
19. [Cutaneous plasmacytomas following treatment of IgA kappa multiple myeloma].
Ortín X; Llorente A; Martínez S; Ugarriza A
Med Clin (Barc); 2004 Oct; 123(15):597-8. PubMed ID: 15535948
[No Abstract] [Full Text] [Related]
20. Melphalan-induced cardiotoxicity: ventricular arrhythmias.
Yanamandra U; Gupta S; Khadwal A; Malhotra P
BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 27979851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
